Overview

Gene Location [1]
8q24.21
Variant Type
Amplification
Gene
MYC

MYC Amplification is present in 3.97% of AACR GENIE cases, with breast invasive ductal carcinoma, lung adenocarcinoma, colon adenocarcinoma, prostate adenocarcinoma, and invasive breast carcinoma having the greatest prevalence [4].

Top Disease Cases with MYC Amplification

Significance of MYC Amplification in Diseases

Diffuse Large B-Cell Lymphoma +

Malignant Solid Tumor +

Medulloblastoma +

Non-Hodgkin Lymphoma +

Breast Carcinoma +

Mature B-Cell Lymphoma/Leukemia +

Medulloblastoma, Non-WNT/Non-SHH +

Non-Small Cell Lung Carcinoma +

Central Nervous System Embryonal Neoplasm +

Lymphoma +

Follicular Lymphoma +

Gastrointestinal Stromal Tumor +

Central Nervous System Ganglioneuroblastoma +

Central Nervous System Neuroblastoma +

Chronic Lymphocytic Leukemia +

Hodgkin Lymphoma +

Marginal Zone Lymphoma +

Medulloblastoma, SHH-Activated +

Medulloepithelioma +

Transformed Non-Hodgkin Lymphoma +

Large Cell/Anaplastic Medulloblastoma +

Esophageal Adenocarcinoma +

Adenocarcinoma Of The Gastroesophageal Junction +

Ovarian Carcinoma +

Osteosarcoma +

Prostate Carcinoma +

Esophageal Squamous Cell Carcinoma +

Small Cell Lung Carcinoma +

Colorectal Carcinoma +

Gastric Adenocarcinoma +

Solid Neoplasm +

Mantle Cell Lymphoma +

Anaplastic Astrocytoma +

Soft Tissue Sarcoma +

B-Cell Non-Hodgkin Lymphoma +

Head And Neck Squamous Cell Carcinoma +

Diffuse Glioma +

Malignant Glioma +

Glioblastoma +

Leiomyosarcoma +

Papillary Renal Cell Carcinoma +

Central Nervous System Neoplasm +

Clear Cell Renal Cell Carcinoma +

Renal Cell Carcinoma +

Neuroblastoma +

Pleural Mesothelioma +

Anaplastic Astrocytoma, IDH-Mutant +

Anaplastic Ependymoma +

Anaplastic Oligodendroglioma +

Anaplastic Oligodendroglioma, IDH-Mutant And 1p/19q-Codeleted +

Anaplastic Pleomorphic Xanthoastrocytoma +

Atypical Teratoid/Rhabdoid Tumor +

Burkitt Lymphoma +

Central Nervous System Lymphoma +

Desmoplastic/Nodular Medulloblastoma +

Diffuse Midline Glioma, H3 K27M-Mutant +

Double-Hit Lymphoma +

Embryonal Tumor With Multilayered Rosettes, C19MC-Altered +

Embryonal Tumor With Multilayered Rosettes, Not Otherwise Specified +

Ependymoma +

Ependymoma, RELA Fusion-Positive +

Esophageal Adenosquamous Carcinoma +

Gastric Adenosquamous Carcinoma +

Gastric Squamous Cell Carcinoma +

Hairy Cell Leukemia +

High-Grade Glioma, NOS +

Intraocular Lymphoma +

Lymphoplasmacytic Lymphoma +

Mature T-Cell And NK-Cell Lymphoma/Leukemia +

Medulloblastoma With Extensive Nodularity +

Medulloblastoma, WNT-Activated +

Multiple Myeloma +

Peritoneal Mesothelioma +

Pineoblastoma +

Small Intestinal Lymphoma +

Small Lymphocytic Leukemia +

Small Lymphocytic Lymphoma +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.

Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.

4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

5. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.